podcast.de
Anmeldung
Anmeldung Registrierung
Auto Hell Dunkel
Erweiterte Suche
  1. Startseite
  2. Podcasts
  3. Medizin - Open Access LMU - Teil 14/22 Podcast
  4. Monthly intravenous methylprednisolone in relapsing-remitting multiple sclerosis - reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations
Background: Intravenous methylprednisolone (IV-MP) is an
established treatment for multiple sclerosis ( MS) relapses,
accompanied by rapid, though transient reduction of gadolinium
enhancing (Gd+) lesions on brain MRI. Intermittent IV-MP, alone or
with immunomodulators, has been suggested but insufficiently
studied as a strategy to prevent relapses. Methods: In an open,
single-cross-over study, nine patients with relapsing-remitting MS
(RR-MS) underwent cranial Gd-MRI once monthly for twelve months.
From month six on, they received a single i.v.-infusion of 500 mg
methylprednisolone ( and oral tapering for three days) after the
MRI. Primary outcome measure was the mean number of Gd+ lesions
during treatment vs. baseline periods; T2 lesion volume and monthly
plasma concentrations of cortisol, ACTH and prolactin were
secondary outcome measures. Safety was assessed clinically, by
routine laboratory and bone mineral density measurements. Soluble
immune parameters (sTNF-RI, sTNF-RII, IL1-ra and sVCAM-1) and
neuroendocrine tests ( ACTH test, combined dexamethasone/CRH test)
were additionally analyzed. Results: Comparing treatment to
baseline periods, the number of Gd+ lesions/scan was reduced in
eight of the nine patients, by a median of 43.8% ( p = 0.013,
Wilcoxon). In comparison, a pooled dataset of 83 untreated RR-MS
patients from several studies, selected by the same clinical and
MRI criteria, showed a non-significant decrease by a median of 14%
( p = 0.32). T2 lesion volume decreased by 21% during treatment ( p
= 0.001). Monthly plasma prolactin showed a parallel decline ( p =
0.027), with significant cross-correlation with the number of Gd+
lesions. Other hormones and immune system variables were unchanged,
as were ACTH test and dexamethasone-CRH test. Treatment was well
tolerated; routine laboratory and bone mineral density were
unchanged. Conclusion: Monthly IV-MP reduces inflammatory activity
and T2 lesion volume in RR-MS.

Weitere Episoden

External quality assessment of urinary methylmalonic acid quantification - results of a pilot study

External quality assessment of urinary methylmalonic acid quantification - results of a pilot study

vor 19 Jahren
Use of novel serum markers in clinical follow-up of Sertoli-Leydig cell turnours

Use of novel serum markers in clinical follow-up of Sertoli-Leydig cell turnours

vor 19 Jahren
Free serum cortisol: quantification applying equilibrium dialysis or ultrafiltration and an automated immunoassay system

Free serum cortisol: quantification applying equilibrium dialysis or ultrafiltration and an automated immunoassay system

vor 19 Jahren
Die Biegestabprothese: ein experimenteller Ansatz zur metaphysären Hüftendoprothetik

Die Biegestabprothese: ein experimenteller Ansatz zur metaphysären Hüftendoprothetik

vor 19 Jahren
ASCO 2007: What remains important for breast cancer systemic therapy in the routine setting?

ASCO 2007: What remains important for breast cancer systemic therapy in the routine setting?

vor 19 Jahren
Alle Episoden anzeigen
In Podcasts werben
Schalte jetzt Werbung in Podcasts.
Episode melden

„Monthly intravenous methylprednisolone in relapsing-remitting multiple sclerosis - reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations“

Worum geht es? Danach fragen wir noch nach dem Grund.

Abonnenten

Teilen

Mein Archiv

Deine Privatkopie der Folgen, die du nicht verlieren willst.

Podcast-Folgen verschwinden. Feeds werden auf die letzten Episoden gekürzt, Hoster räumen alte Dateien ab, Formate wechseln den Anbieter und lassen ihr Archiv zurück. Mit „Mein Archiv“ sichert podcast.de die Folgen deiner Podcasts für dich — angefangen bei den ältesten, denn die sind zuerst weg.

  • Deine gesicherten Folgen bleiben hörbar, auch wenn das Original offline geht.
  • Auch Folgen, die im heutigen Feed gar nicht mehr stehen — podcast.de kennt sie noch.
  • Herunterladen bleibt möglich, solange die Folge beim Podcaster liegt. Der zählt seine Abrufe wie bisher.
Startet bald

Sei beim Start von Mein Archiv dabei

Mein Archiv ist fast fertig. Trag dich ein, dann bekommst du eine E-Mail, sobald es losgeht – und bist von Anfang an dabei. Wir schreiben dir nur zum Start, keine Werbung, keine Weitergabe deiner Daten.

Du bekommst zuerst eine Bestätigungsmail. Abmelden geht jederzeit. Datenschutz